Cost-Effectiveness of Zoledronic Acid to Prevent and Treat Postmenopausal Osteoporosis in Comparison with Routine Medical Treatment
Keywords:
Cost-effectiveness, Cost-benefit, Zoledronic acid, Osteoporosis, PostmenopausalAbstract
Introduction: Fractures caused by osteoporosis are prevalent among elderly females, which reduce quality of life significantly. This study aimed at comparing cost-effectiveness of Zoledronic acid in preventing and treating post-menopause osteoporosis as compared with routine medical treatment.
Methods: This cost-effectiveness study was carried out retrospectively from the Ministry of Health and insurance organizations perspective. Costs were evaluated based on the cost estimation of a sample of patients. Outcomes were obtained from a systematic review. The Cost-Effectiveness Ratio (CER) and incremental cost-effectiveness ratio (ICER) for outcome of femoral neck Bone Mineral Density (BMD), hip trochanter BMD, total hip BMD and lumbar spine BMD and cost-benefit of consuming Zoledronic Acid were calculated for fracture outcome obtained from reviewing hospital records.
Results: The results and the ICER calculated for study outcomes indicated that one percent increase of BMD on femoral neck BMD requires further cost of $386. One percent increase of BMD on hip trochanter BMD requires further cost of $264. One percent increase of BMD on total hip BMD requires further cost of $388, one percent increase of BMD on lumbar spine BMD requires further cost of $347. The Cost Benefit Analysis (CBA) calculated for vertebral and hip fracture, non-vertebral fracture, any clinical fracture, and morphometric fracture for a 36-month period were about 0.82, 0.57, and 1.06, respectively. Vertebral and hip fractures, and non-vertebral fractures or any clinical fracture for a 12-month period were calculated as 1.14 and 0.64, respectively. In other words, Zoledronic acid consumption approach is a cheaper and better approach based on an economic assessment, and it can be considered as a dominant approach.
Conclusion: According to the cost-effectiveness of zoledronic acid in the prevention and treatment of osteoporosis in women, despite the costs, it is recommended that insurance coverage for the drug should be considered in the period after menopause and the benefits of this drug. This can reduce the costs imposed on the patients and also it can reduce the economic burden on the community, particularly as a result of the fracture.
References
Fardellone P, Cortet B, Legrand E, Bresse X, Bisot-Locard S, Vigneron AM, et al. Cost-effectiveness
model of using zoledronic acid once a year versus current treatment strategies in postmenopausal
osteoporosis. Joint Bone Spine. 2010; 77(1): 53-7. doi: 10.1016/j.jbspin.2009.04.009. PMID: 20034831.
Meybodi HA, Heshmat R, Maasoumi Z, Soltani A, Hossein-Nezhad A, Keshtkar AA, et al. Iranian
Osteoporosis Research Network: Background, mission and its role in osteoporosis management. Iranian
Journal of Public Health. 2008; 37(sup): 1-6.
Kamienski M, Tate D, Vega M. The Silent Thief: Diagnosis and Management of Osteoporosis. Orthop
Nurs. 2011; 30(3): 162-71. doi: 10.1097/NOR.0b013e318219ab9d. PMID: 21597343.
Roush K. Prevention and treatment of osteoporosis in postmenopausal women: a review. Am J Nurs. 2011;
(8): 26-35. doi: 10.1097/01.NAJ.0000403358.44058.f7. PMID: 21795930.
Burge R, Dawson‐Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and Economic
Burden of Osteoporosis‐Related Fractures in the United States, 2005-2025. J Bone Miner Res. 2007;
(3): 465-75. doi: 10.1359/jbmr.061113. PMID: 17144789.
Al-Anazi AF, Qureshi VF, Javaid K, Qureshi S. Preventive effects of phytoestrogens against
postmenopausal osteoporosis as compared to the available therapeutic choices: An overview. J Nat Sci Biol
Med. 2011; 2(2): 154-63. doi: 10.4103/0976-9668.92322. PMID: 22346228, PMCID: PMC3276006.
Aghaalikhani M, Taheri tanjani P, Hosainpoor azari A, Mousavi M, Rezapour M, Amini Y, et al. The
prevalence of osteoporosis in elderly hospital patients over 60 years of age, sex, relationship Taleghani
Hospital. Journal of Ilam University of Medical Sciences. 2012; 20(5): 94-102.
Demontiero O, Duque G. Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging. 2009;
: 153-64. doi: 10.2147/CIA.S5065. PMID: 19503777, PMCID: PMC2685236.
Mottaghi P. Intravenous bisphosphonates for postmenopausal osteoporosis. J Res Med Sci. 2010; 15(3):
-84. PMID: 21526078, PMCID: PMC3082804.
Keating GM, Scott LJ. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
Drugs. 2007; 67(5): 793-804. PMID: 17385948.
Lourwood DL. The pharmacology and therapeutic utility of bisphosphonates. Pharmacotherapy. 1998;
(4): 779-89. PMID: 9692651.
Püntmann I, Schmacke N, Melander A, Lindberg G, Mühlbauer B. EVITA: a tool for the early EValuation
of pharmaceutical Innovations with regard to Therapeutic Advantage. BMC clinical pharmacology. 2010;
(1): 5. doi: 10.1186/1472-6904-10-5. PMID: 20233429, PMCID: PMC2858124.
Williams IP, Bryan S. Cost-effectiveness analysis and formulary decision making in England: findings
from research. Soc Sci Med. 2007; 65(10): 2116-29. doi: 10.1016/j.socscimed.2007.06.009. PMID:
Doortaj rabari A, Bagheri P, Vafaei Z, Haghdoost A, Halimi L, Farhangnia M, et al. The prevalence of
osteoporosis in Iranian women (meta-analysis). Journal of Endocrinology and Metabolism of Iran. 2011;
(13): 315-25.
Gharibdoust F. Osteoporosis. Tehran, Andishmand Publishers. 1992.
Abolhassani F, Mohammadi M, Soltani A. Burden ofosteoporosis in Iran. Iranian Journal of Public Health.
; 0(0): 18-28.
Ardeshir larijani M, Gooya M, Moohajeri M, Bastan M, Ranjbaromrani G, Bahrami A, et al. Osteoporosis
diagnosis and treatment. Journal of Medical Council of Islamic Republic Iran. 1993.
Reid IR, Brown J, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous Zoledronic acid
in postmenopousal women with low bone mineral density. The New England Journal of Medicine. 2002;
(9): 653-61. doi: 10.1056/NEJMoa011807.
Lyseng-Williamson KA. Zoledronic acid: a review of its use in breast cancer. Drugs. 2008; 68(18): 2661- 82. doi: 10.2165/0003495-200868180-00010. PMID: 19093706.
Reed SD, Radeva JI, Glendenning GA, Saad F, Schulman KA. Cost-effectiveness of zoledronic acid for the
prevention of skeletal complications in patients with prostate cancer. J Urol. 2004; 171(4): 1537-42. doi:
1097/01.ju.0000116777.94426.60. PMID: 15017215.
Botteman M, Barghout V, Stephens J, Hay J, Brandman J, Aapro M. Cost effectiveness of bisphosphonates
in the management of breast cancer patients with bone metastases. Ann Oncol. 2006; 17(7): 1072-82. doi:
1093/annonc/mdl093. PMID: 16670202.
Botteman MF, Meijboom M, Foley I, Stephens JM, Chen YM, Kaura S. Cost-effectiveness of zoledronic
acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced
renal cell carcinoma: application to France, Germany, and the United Kingdom. Eur J Health Econ. 2011;
(6): 575-88. doi: 10.1007/s10198-010-0272-0. PMID: 20809091, PMCID: PMC3197935.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
